Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH. Herben VM, et al. Cancer Chemother Pharmacol. 2002 Jul;50(1):59-64. doi: 10.1007/s00280-002-0454-2. Epub 2002 Apr 5. Cancer Chemother Pharmacol. 2002. PMID: 12111113 Clinical Trial.
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. J Clin Oncol. 1999 Jun;17(6):1906-14. doi: 10.1200/JCO.1999.17.6.1906. J Clin Oncol. 1999. PMID: 10561232 Clinical Trial.
Oral topotecan: bioavailablity and effect of food co-administration.
Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH, Schellens JH. Herben VM, et al. Br J Cancer. 1999 Jul;80(9):1380-6. doi: 10.1038/sj.bjc.6690532. Br J Cancer. 1999. PMID: 10424739 Free PMC article. Clinical Trial.
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. J Clin Oncol. 1999 Mar;17(3):747-55. doi: 10.1200/JCO.1999.17.3.747. J Clin Oncol. 1999. PMID: 10071262 Clinical Trial.
17 results